Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice ; volume:17 ; number:1 ; day:1 ; month:3 ; year:2016 ; pages:1-6 ; date:12.2016
BMC musculoskeletal disorders ; 17, Heft 1 (1.3.2016), 1-6, 12.2016
- Urheber
-
Catay, Erika
- Beteiligte Personen und Organisationen
-
Bravo, Maximiliano
Rosa, Javier
Soriano, Enrique R.
SpringerLink (Online service)
- DOI
-
10.1186/s12891-016-0959-1
- URN
-
urn:nbn:de:1111-2016073036710
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Catay, Erika
- Bravo, Maximiliano
- Rosa, Javier
- Soriano, Enrique R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
Real-world retention rates of biologics in patients with rheumatoid arthritis
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Methotrexate treatment before use of biologics in rheumatoid arthritis: Analysis of guideline compliance
Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
Real-world retention rates of biologics in patients with rheumatoid arthritis
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Methotrexate treatment before use of biologics in rheumatoid arthritis: Analysis of guideline compliance
Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
Real-world retention rates of biologics in patients with rheumatoid arthritis
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Methotrexate treatment before use of biologics in rheumatoid arthritis: Analysis of guideline compliance
Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?
Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
Serum level of IFNβ distinguishes early from late relapses after biologics withdrawal in rheumatoid arthritis
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?